Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens.
Kourea HP, Dimitrakopoulos FI, Koliou GA, Batistatou A, Papadopoulou K, Bobos M, Asimaki-Vlachopoulou A, Chrisafi S, Pavlakis K, Chatzopoulos K, Galani E, Pentheroudakis G, Pectasides D, Bafaloukos D, Res E, Papakostas P, Koutras A, Kotoula V, Fountzilas G. Kourea HP, et al. Among authors: batistatou a. Cancer Res Treat. 2022 Oct;54(4):1053-1064. doi: 10.4143/crt.2021.748. Epub 2021 Nov 17. Cancer Res Treat. 2022. PMID: 34793664 Free PMC article.
Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.
Pentheroudakis G, Batistatou A, Kalogeras KT, Kronenwett R, Wirtz RM, Bournakis E, Eleftheraki AG, Pectasides D, Bobos M, Papaspirou I, Kamina S, Gogas H, Koutras AK, Pavlidis N, Fountzilas G. Pentheroudakis G, et al. Among authors: batistatou a. Breast Cancer Res Treat. 2011 May;127(1):179-93. doi: 10.1007/s10549-011-1427-0. Epub 2011 Mar 9. Breast Cancer Res Treat. 2011. PMID: 21390496 Free article.
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G. Skarlos P, et al. Among authors: batistatou a. Cancer Chemother Pharmacol. 2012 Feb;69(2):533-46. doi: 10.1007/s00280-011-1730-9. Epub 2011 Sep 8. Cancer Chemother Pharmacol. 2012. PMID: 21901395
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study.
Psyrri A, Kalogeras KT, Kronenwett R, Wirtz RM, Batistatou A, Bournakis E, Timotheadou E, Gogas H, Aravantinos G, Christodoulou C, Makatsoris T, Linardou H, Pectasides D, Pavlidis N, Economopoulos T, Fountzilas G. Psyrri A, et al. Among authors: batistatou a. Ann Oncol. 2012 Jun;23(6):1422-7. doi: 10.1093/annonc/mdr527. Epub 2011 Nov 4. Ann Oncol. 2012. PMID: 22056852 Free article.
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M, Kalofonos HP, Eleftheraki AG, Timotheadou E, Bafaloukos D, Christodoulou C, Markopoulos C, Briasoulis E, Papakostas P, Samantas E, Kosmidis P, Stathopoulos GP, Karanikiotis C, Pectasides D, Dimopoulos MA, Fountzilas G. Gogas H, et al. Among authors: batistatou a. Breast Cancer Res Treat. 2012 Apr;132(2):609-19. doi: 10.1007/s10549-011-1913-4. Epub 2011 Dec 21. Breast Cancer Res Treat. 2012. PMID: 22187126 Clinical Trial.
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
Fountzilas G, Valavanis C, Kotoula V, Eleftheraki AG, Kalogeras KT, Tzaida O, Batistatou A, Kronenwett R, Wirtz RM, Bobos M, Timotheadou E, Soupos N, Pentheroudakis G, Gogas H, Vlachodimitropoulos D, Polychronidou G, Aravantinos G, Koutras A, Christodoulou C, Pectasides D, Arapantoni P. Fountzilas G, et al. Among authors: batistatou a. J Transl Med. 2012 Jan 12;10:10. doi: 10.1186/1479-5876-10-10. J Transl Med. 2012. PMID: 22240029 Free PMC article.
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, Malamou-Mitsi V, Miliaras S, Chrisafi S, Papadopoulos S, Sotiropoulou M, Filippidis T, Gogas H, Koletsa T, Bafaloukos D, Televantou D, Kalogeras KT, Pectasides D, Skarlos DV, Koutras A, Dimopoulos MA. Fountzilas G, et al. Among authors: batistatou a. PLoS One. 2012;7(6):e37946. doi: 10.1371/journal.pone.0037946. Epub 2012 Jun 5. PLoS One. 2012. PMID: 22679488 Free PMC article.
229 results